EBS PHARMA
ActiveSummary
EBS PHARMA has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €20,714 and a net result of €22,677. Equity remains stable across the filed financial years (±1.2% per year). Its solvency ranks better than 47% of 1,883 sector peers (NACE 10, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Directors
Mandate history
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| Tri-Sana |
|
Owners and capital
Owners
1 ownerChain of control
- Tri-Sana
- EBS PHARMA
Highest known parent: Tri-Sana. The sources do not say who stands above it.
Owners 1
- Tri-SanaparentSourceact 01-10-2026100%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
- Tri-Sana (BE 0839.827.582) all shares
The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.